March 27, 1988

Robert Turner, M.D.
The Bowman Gray School of Medicine
Department of Medicine
Section on Rheumatology
300 South Hawthorne Road
Winston-Salem, North Carolina 27103

Dear Dr. Turner:

I am pleased that at last we got our report on the long study using clotrimazole vs. a placebo.

As I expected from the start, by virtue of study design and avoidance of our clinical information regarding the so-called "Jarisch-Herxheimer" effect, results were something less than spectacular.

I support my conclusion in part on the last statement that says: "...showed statistical evidence of toxicity but not efficacy for Clotrimazole in the treatment of RA."

The very symptoms that are being classed as "toxic" are Herxheimer symptoms for the most part. We have found that when these symptoms are lived through and passed, that the same amount of C does not create them, and the person achieves wellness.

In part I criticize the study design -- and always have -- because those who are most likely to show results are those who have the greatest Herxheimer falsely attributed to C toxicity, and these same are the ones to drop out, leaving a disproportionate number of patients who would not respond in the study. Since our clinical studies show a consistent 80% response rate, this study most probably reflects a disproportionate population drawn from the 20% group. Neither Simoons nor you folks compensated for this feature in the study design despite my complaints made in writing and in person.

Finally, the study is not consistent with the results of our clinical studies made world-wide in multi-clinic settings, nor does it correlate with the basic research findings of the effect of Clotrimazole on human bio-chemistry made independently at Medical College of Virginia.
In short, I find the study at best is inconclusive and will most probably delay the acceptance of the only treatment modality that is bringing about remission/cure of Rheumatoid Disease.

To us, this means raising more money, and hereafter paying special attention to the study design to handle those important parameters not designed into this one.

I hope to Dr. Dennison, it means also reporting our view, and also in any articles to be published in professional journals.

Meanwhile I want to thank you for your professional courtesy and interest in performing this study for us, and I look forward to reading the final report.

Cordially,

Perry A. Chapdelaine, Sr.

C: William Dennison, M.D.
Bradley Wells
Gus Prosch, Jr., M.D.
John Baron, D.O.
Dr. Paul K. Pybus